JP2021167351A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021167351A5 JP2021167351A5 JP2021121236A JP2021121236A JP2021167351A5 JP 2021167351 A5 JP2021167351 A5 JP 2021167351A5 JP 2021121236 A JP2021121236 A JP 2021121236A JP 2021121236 A JP2021121236 A JP 2021121236A JP 2021167351 A5 JP2021167351 A5 JP 2021167351A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- compound according
- group
- pharmaceutical composition
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 29
- 229910052739 hydrogen Inorganic materials 0.000 claims 18
- -1 methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino Chemical group 0.000 claims 16
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 239000001257 hydrogen Substances 0.000 claims 11
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 9
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims 9
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims 9
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 8
- 150000002431 hydrogen Chemical class 0.000 claims 8
- 229940124597 therapeutic agent Drugs 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 125000003107 substituted aryl group Chemical group 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 206010039491 Sarcoma Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- 102100022464 5'-nucleotidase Human genes 0.000 claims 2
- 201000009030 Carcinoma Diseases 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 229960005475 antiinfective agent Drugs 0.000 claims 2
- 239000004599 antimicrobial Substances 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 230000004761 fibrosis Effects 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 210000001550 testis Anatomy 0.000 claims 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000003017 Aortic Valve Stenosis Diseases 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical compound CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010011732 Cyst Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 206010012442 Dermatitis contact Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010062016 Immunosuppression Diseases 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 201000010208 Seminoma Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 230000001919 adrenal effect Effects 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 208000002029 allergic contact dermatitis Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 206010002906 aortic stenosis Diseases 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 125000001246 bromo group Chemical group Br* 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 210000002808 connective tissue Anatomy 0.000 claims 1
- 208000031513 cyst Diseases 0.000 claims 1
- 230000002357 endometrial effect Effects 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 210000003128 head Anatomy 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 230000001506 immunosuppresive effect Effects 0.000 claims 1
- 125000002346 iodo group Chemical group I* 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 210000000265 leukocyte Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 210000003739 neck Anatomy 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 229960003301 nivolumab Drugs 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 229960002621 pembrolizumab Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 208000020352 skin basal cell carcinoma Diseases 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 125000004014 thioethyl group Chemical group [H]SC([H])([H])C([H])([H])* 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023121750A JP7698677B2 (ja) | 2016-01-08 | 2023-07-26 | ５’ヌクレオチダーゼ，エクトのモジュレーター及びその使用 |
| JP2025099433A JP2025123371A (ja) | 2016-01-08 | 2025-06-13 | ５’ヌクレオチダーゼ，エクトのモジュレーター及びその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662276564P | 2016-01-08 | 2016-01-08 | |
| US62/276,564 | 2016-01-08 | ||
| US201662324077P | 2016-04-18 | 2016-04-18 | |
| US62/324,077 | 2016-04-18 | ||
| JP2018554643A JP6920344B2 (ja) | 2016-01-08 | 2017-01-06 | ５’ヌクレオチダーゼ，エクトのモジュレーター及びその使用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018554643A Division JP6920344B2 (ja) | 2016-01-08 | 2017-01-06 | ５’ヌクレオチダーゼ，エクトのモジュレーター及びその使用 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023121750A Division JP7698677B2 (ja) | 2016-01-08 | 2023-07-26 | ５’ヌクレオチダーゼ，エクトのモジュレーター及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021167351A JP2021167351A (ja) | 2021-10-21 |
| JP2021167351A5 true JP2021167351A5 (cg-RX-API-DMAC7.html) | 2022-03-10 |
| JP7322104B2 JP7322104B2 (ja) | 2023-08-07 |
Family
ID=59274491
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018554643A Active JP6920344B2 (ja) | 2016-01-08 | 2017-01-06 | ５’ヌクレオチダーゼ，エクトのモジュレーター及びその使用 |
| JP2021121236A Active JP7322104B2 (ja) | 2016-01-08 | 2021-07-26 | ５’ヌクレオチダーゼ，エクトのモジュレーター及びその使用 |
| JP2023121750A Active JP7698677B2 (ja) | 2016-01-08 | 2023-07-26 | ５’ヌクレオチダーゼ，エクトのモジュレーター及びその使用 |
| JP2025099433A Pending JP2025123371A (ja) | 2016-01-08 | 2025-06-13 | ５’ヌクレオチダーゼ，エクトのモジュレーター及びその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018554643A Active JP6920344B2 (ja) | 2016-01-08 | 2017-01-06 | ５’ヌクレオチダーゼ，エクトのモジュレーター及びその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023121750A Active JP7698677B2 (ja) | 2016-01-08 | 2023-07-26 | ５’ヌクレオチダーゼ，エクトのモジュレーター及びその使用 |
| JP2025099433A Pending JP2025123371A (ja) | 2016-01-08 | 2025-06-13 | ５’ヌクレオチダーゼ，エクトのモジュレーター及びその使用 |
Country Status (29)
Families Citing this family (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017120508A1 (en) | 2016-01-08 | 2017-07-13 | Arcus Biosciences, Inc. | Modulators of 5'-nucleotidase, ecto and the use thereof |
| US10472364B2 (en) | 2016-09-09 | 2019-11-12 | Calithera Biosciences, Inc. | Ectonucleotidase inhibitors and methods of use thereof |
| WO2018094148A1 (en) * | 2016-11-18 | 2018-05-24 | Arcus Biosciences, Inc. | Inhibitors of cd73-mediated immunosuppression |
| CN117285525A (zh) | 2016-12-08 | 2023-12-26 | 豪夫迈·罗氏有限公司 | 作为GABAAα5 PAM的新型异噁唑基醚衍生物 |
| CA3047988A1 (en) * | 2016-12-22 | 2018-06-28 | Calithera Biosciences, Inc. | Ectonucleotidase inhibitors and methods of use thereof |
| CA3051640A1 (en) | 2017-03-16 | 2018-09-20 | Innate Pharma | Compositions and methods for treating cancer |
| WO2018208980A1 (en) | 2017-05-10 | 2018-11-15 | Oric Pharmaceuticals, Inc. | Cd73 inhibitors |
| JP7274469B2 (ja) | 2017-10-06 | 2023-05-16 | イナート・ファルマ・ソシエテ・アノニム | Ｃｄ３９／ｃｄ７３軸によるｔ細胞活性の回復 |
| US11377469B2 (en) | 2017-11-03 | 2022-07-05 | Oric Pharmaceuticals, Inc. | CD73 inhibitors |
| CN111094317B (zh) * | 2017-12-29 | 2023-03-31 | 上海和誉生物医药科技有限公司 | 一种具有cd73抑制活性的膦酸衍生物、其制备方法和应用 |
| TWI702954B (zh) * | 2018-03-01 | 2020-09-01 | 美商美國禮來大藥廠 | Cd73抑制劑 |
| AU2019231781B2 (en) * | 2018-03-09 | 2025-02-13 | Arcus Biosciences, Inc. | Parenterally administered immune enhancing drugs |
| MX2020011542A (es) * | 2018-04-30 | 2020-11-24 | Oric Pharmaceuticals Inc | Inhibidores de cd73. |
| EP3810109B1 (en) | 2018-05-31 | 2024-08-07 | Peloton Therapeutics, Inc. | Compounds and compositions for inhibiting cd73 |
| BR112020024412A8 (pt) | 2018-06-18 | 2023-03-21 | Innate Pharma | Anticorpos, composição farmacêutica, kit, ácido nucleico, célula hospedeira, métodos de tratamento ou prevenção de câncer, de redução da atividade, de aumento da atividade e de aumento da ativação |
| WO2020037275A1 (en) * | 2018-08-17 | 2020-02-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Purine and pyrimidine nucleotides as ecto-5'-nucleotidase inhibitors |
| EP3843742A4 (en) | 2018-08-28 | 2022-04-20 | Jiangsu Hengrui Medicine Co., Ltd. | CD73 INHIBITORS AND THEIR THERAPEUTIC USES |
| CN110885352B (zh) * | 2018-09-11 | 2023-02-24 | 润佳（苏州）医药科技有限公司 | Cd73抑制剂及其药学应用 |
| US11530234B2 (en) | 2018-09-11 | 2022-12-20 | Risen (Suzhou) Pharma Tech Co., Ltd. | CD73 inhibitors and pharmaceutical uses thereof |
| US10881681B2 (en) | 2018-09-11 | 2021-01-05 | Risen (Suzhou) Pharma Tech Co., Ltd. | CD73 inhibitors and pharmaceutical uses thereof |
| US11819512B2 (en) | 2018-12-13 | 2023-11-21 | Arcus Biosciences, Inc. | Solid forms of a CD73 inhibitor and the use thereof |
| AU2020205753B2 (en) | 2019-01-11 | 2025-05-29 | Omeros Corporation | Methods and compositions for treating cancer |
| WO2020151707A1 (zh) * | 2019-01-22 | 2020-07-30 | 江苏恒瑞医药股份有限公司 | 一种新型的小分子cd73抑制剂、其制备方法及其在医药上的应用 |
| US12453738B2 (en) * | 2019-03-12 | 2025-10-28 | Arcus Biosciences, Inc. | Treatment of oncogene-driven cancers |
| WO2020205527A1 (en) | 2019-03-29 | 2020-10-08 | Arcus Biosciences, Inc. | Treatment of cancer utilizing an identified adenosine fingerprint |
| WO2020205538A1 (en) * | 2019-03-29 | 2020-10-08 | Eternity Bioscience Inc. | Cd73 inhibitors and therapeutic uses thereof |
| EP3952874A4 (en) * | 2019-04-05 | 2022-12-28 | Prelude Therapeutics, Incorporated | SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 |
| WO2020210938A1 (en) * | 2019-04-15 | 2020-10-22 | Bioardis Llc | Quinazoline derivatives as cd73 inhibitors |
| WO2020210970A1 (en) * | 2019-04-16 | 2020-10-22 | Bioardis Llc | Imidazotriazine derivatives as cd73 inhibitors |
| TWI821559B (zh) * | 2019-04-28 | 2023-11-11 | 大陸商上海和譽生物醫藥科技有限公司 | 一種cd73抑制劑，其製備方法和應用 |
| KR20220034780A (ko) * | 2019-06-14 | 2022-03-18 | 써던 리서취 인스티튜트 | 2,4,7-치환된-7-데아자-2'-데옥시-2'-플루오로아라비노실 뉴클레오사이드 및 뉴클레오타이드 전구약물 및 이의 용도 |
| WO2021040356A1 (en) * | 2019-08-23 | 2021-03-04 | Kainos Medicine, Inc. | C-nucleosides, c-nucleotides and their analogs, equivalents and prodrugs thereof for ectonucleotidase inhibition |
| BR112022001365A2 (pt) * | 2019-08-29 | 2022-06-07 | Lilly Co Eli | Formas cristalinas de um inibidor de cd73 |
| DK4051688T3 (da) | 2019-10-30 | 2025-06-30 | Oric Pharmaceuticals Inc | Cd73-hæmmere |
| TW202131932A (zh) * | 2019-11-05 | 2021-09-01 | 美商博奥阿迪斯有限公司 | 作為cd73抑制劑的化合物 |
| US11633416B1 (en) | 2020-03-06 | 2023-04-25 | Arcus Biosciences, Inc. | Oral formulations of CD73 compounds |
| KR20220155593A (ko) | 2020-03-19 | 2022-11-23 | 아르커스 바이오사이언시즈 인코포레이티드 | Hif-2알파의 억제제로서의 테트랄린 및 테트라히드로퀴놀린 화합물 |
| EP4157875A1 (en) | 2020-06-02 | 2023-04-05 | Arcus Biosciences, Inc. | Antibodies to tigit |
| WO2021247188A1 (en) | 2020-06-05 | 2021-12-09 | Bristol-Myers Squibb Company | Cd73 antagonist potency assay and methods of use thereof |
| AU2021292195A1 (en) * | 2020-06-17 | 2023-01-05 | Arcus Biosciences, Inc. | Crystalline forms of a CD73 inhibitor and uses thereof |
| CN115702150A (zh) * | 2020-07-07 | 2023-02-14 | 贝达药业股份有限公司 | Cd73抑制剂及其在医药上的应用 |
| EP4212524A4 (en) * | 2020-09-08 | 2024-08-28 | Betta Pharmaceuticals Co., Ltd | Cd73 inhibitor and application thereof in medicine |
| WO2022095953A1 (zh) * | 2020-11-05 | 2022-05-12 | 武汉人福创新药物研发中心有限公司 | 哒嗪炔烃类化合物及其用途 |
| EP4242204A4 (en) * | 2020-11-05 | 2024-10-09 | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company | CD73 INHIBITOR AND USE THEREOF |
| US20240024346A1 (en) * | 2020-11-25 | 2024-01-25 | Risen (Suzhou) Pharma Tech Co., Ltd. | Cd73 inhibitors and pharmaceutical uses thereof |
| CA3200232A1 (en) * | 2020-11-25 | 2022-06-02 | Yuhua Zhang | Cd73 inhibitors and pharmaceutical uses thereof |
| EP4273153A4 (en) * | 2020-12-29 | 2024-05-08 | Zhejiang Vimgreen Pharmaceuticals, Ltd | ADENOSINE A3 RECEPTOR AGONIST, PREPARATION METHOD THEREFOR AND USE THEREOF |
| US20240368204A1 (en) * | 2021-05-11 | 2024-11-07 | Xizang Haisco Pharmaceutical Co., Ltd. | Small molecular cd73 antagonist and use thereof |
| EP4341262A1 (en) | 2021-05-21 | 2024-03-27 | Arcus Biosciences, Inc. | Axl inhibitor compounds |
| CN117295741A (zh) | 2021-05-21 | 2023-12-26 | 艾库斯生物科学有限公司 | Axl化合物 |
| WO2023061319A1 (zh) * | 2021-10-11 | 2023-04-20 | 南京明德新药研发有限公司 | 三并环杂环衍生物 |
| CA3235405A1 (en) | 2021-10-26 | 2023-05-04 | Omar MOUKHA-CHAFIQ | Development of novel clofarabine analogs for cancer therapy |
| JP2024541969A (ja) | 2021-10-29 | 2024-11-13 | アーカス バイオサイエンシズ インコーポレイティド | Ｈｉｆ－２アルファの阻害剤及びその使用方法 |
| CA3256033A1 (en) | 2022-04-13 | 2023-10-19 | Arcus Biosciences, Inc. | POLYTHERAPY FOR THE TREATMENT OF CANCERS EXPRESSING TOO MUCH-2 |
| AU2023264591A1 (en) | 2022-05-02 | 2024-11-07 | Arcus Biosciences, Inc. | Anti-tigit antibodies and uses of the same |
| WO2024015251A1 (en) | 2022-07-15 | 2024-01-18 | Arcus Biosciences, Inc. | Inhibitors of hpk1 and methods of use thereof |
| EP4558501A1 (en) | 2022-07-20 | 2025-05-28 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| CN117466964A (zh) * | 2022-07-21 | 2024-01-30 | 南京烁慧医药科技有限公司 | 双磷酸核苷类化合物及其制备方法 |
| TW202421150A (zh) | 2022-09-14 | 2024-06-01 | 美商阿克思生物科學有限公司 | 艾魯美冷之分散體 |
| US20240140980A1 (en) * | 2022-10-03 | 2024-05-02 | Teon Therapeutics, Inc. | Heterocyclic inhibitors of cd73 for treatment of disease |
| US20240140979A1 (en) * | 2022-10-03 | 2024-05-02 | Teon Therapeutics, Inc. | Heterocyclic inhibitors of cd73 for treatment of disease |
| WO2024081385A1 (en) | 2022-10-14 | 2024-04-18 | Arcus Biosciences, Inc. | Hpk1 inhibitors and methods of use thereof |
| EP4604920A1 (en) | 2022-10-20 | 2025-08-27 | Arcus Biosciences, Inc. | Lyophilized formulations of cd73 compounds |
| WO2024233360A1 (en) | 2023-05-05 | 2024-11-14 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| US20250011318A1 (en) | 2023-05-25 | 2025-01-09 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| CN117924394A (zh) * | 2023-09-05 | 2024-04-26 | 厦门大学 | 核苷酸类化合物及其制备方法和应用、核素靶向探针及其制备方法和应用、药物组合物 |
| WO2025054339A1 (en) | 2023-09-08 | 2025-03-13 | Arcus Biosciences, Inc. | Triazolopyridine compounds as inhibitors of kit |
| WO2025072330A1 (en) | 2023-09-26 | 2025-04-03 | Arcus Biosciences, Inc. | Kit inhibitor compounds and methods of use thereof |
| TW202517260A (zh) | 2023-10-06 | 2025-05-01 | 美商阿克思生物科學有限公司 | Ｃｂｌ—ｂ抑制劑及其使用方法 |
| US12384773B2 (en) | 2023-11-02 | 2025-08-12 | Arcus Biosciences, Inc. | Thiazole compounds and methods of use thereof |
| WO2025113498A1 (zh) * | 2023-12-01 | 2025-06-05 | 无锡和誉生物医药科技有限公司 | 一种cd73抑制剂碱式盐及其制备方法和应用 |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025193759A1 (en) | 2024-03-12 | 2025-09-18 | Gilead Sciences, Inc. | Solid forms of an azolopyrimidine compound |
| WO2025233264A1 (en) | 2024-05-07 | 2025-11-13 | Innate Pharma | Use of cd73 blocking agents in combination with anti-cd20 x cd3 t cell engagers |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5569650A (en) * | 1993-06-11 | 1996-10-29 | Sloan-Kettering Institute For Cancer Research | C-nucleoside isosters of analogs thereof and pharmaceutical compositions |
| DE69729877T2 (de) * | 1996-10-09 | 2005-07-14 | Pharmasset, Ltd. | Mycophenol bisphosponatverbindungen |
| CA2429352A1 (en) | 2000-12-15 | 2002-06-20 | Lieven Stuyver | Antiviral agents for treatment of flaviviridae infections |
| WO2012032513A1 (en) * | 2010-09-07 | 2012-03-15 | Bar-Ilan University | Boranophosphate derivatives for the treatment of osteoarthritis |
| WO2013132489A1 (en) | 2012-03-05 | 2013-09-12 | Bar-Ilan University | Nucleoside 5'-phosphorothioate analogues and uses thereof |
| EP2846788A1 (en) | 2012-05-11 | 2015-03-18 | Akron Molecules AG | Use of compounds for the treatment of pain |
| US9090697B2 (en) | 2013-03-15 | 2015-07-28 | Bayer Healthcare Llc | Methods for treating bleeding disorders |
| FR3011240A1 (fr) * | 2013-10-01 | 2015-04-03 | Centre Nat Rech Scient | Inhibiteurs de 5'-nucleotidases et leurs utilisations therapeutiques |
| BR112016020919A2 (pt) * | 2014-03-12 | 2018-01-23 | Yeda Res & Dev | redução dos níveis ou da atividade sistêmica de células t regulatórias para o tratamento de doença e lesão do snc |
| WO2015164573A1 (en) * | 2014-04-25 | 2015-10-29 | Vitae Pharmaceuticals, Inc. | Purine derivatives as cd73 inhibitors for the treatment of cancer |
| CR20180168A (es) | 2015-08-17 | 2018-06-27 | Lupin Ltd | Derivados de heteroarilo como inhibidores de parp |
| WO2017120508A1 (en) * | 2016-01-08 | 2017-07-13 | Arcus Biosciences, Inc. | Modulators of 5'-nucleotidase, ecto and the use thereof |
| EP3808346B1 (en) | 2016-01-08 | 2023-07-19 | Celgene Corporation | Antiproliferative compounds for use in the treatment of leukemia |
| UY37062A (es) | 2016-01-08 | 2017-08-31 | Syngenta Participations Ag | Derivados de aryl oxadiazol fungicidas |
| AU2019231781B2 (en) | 2018-03-09 | 2025-02-13 | Arcus Biosciences, Inc. | Parenterally administered immune enhancing drugs |
| US11819512B2 (en) | 2018-12-13 | 2023-11-21 | Arcus Biosciences, Inc. | Solid forms of a CD73 inhibitor and the use thereof |
| US11633416B1 (en) | 2020-03-06 | 2023-04-25 | Arcus Biosciences, Inc. | Oral formulations of CD73 compounds |
| AU2021292195A1 (en) | 2020-06-17 | 2023-01-05 | Arcus Biosciences, Inc. | Crystalline forms of a CD73 inhibitor and uses thereof |
-
2017
- 2017-01-06 WO PCT/US2017/012587 patent/WO2017120508A1/en not_active Ceased
- 2017-01-06 SI SI201731439T patent/SI3399984T1/sl unknown
- 2017-01-06 CN CN201780006172.1A patent/CN108697719B/zh active Active
- 2017-01-06 BR BR112018013827-4A patent/BR112018013827B1/pt active IP Right Grant
- 2017-01-06 EP EP17736459.3A patent/EP3399984B1/en active Active
- 2017-01-06 CA CA3009196A patent/CA3009196C/en active Active
- 2017-01-06 FI FIEP17736459.3T patent/FI3399984T3/fi active
- 2017-01-06 AU AU2017206061A patent/AU2017206061B2/en active Active
- 2017-01-06 CA CA3151595A patent/CA3151595A1/en active Pending
- 2017-01-06 IL IL260260A patent/IL260260B2/en unknown
- 2017-01-06 US US15/400,748 patent/US10239912B2/en active Active
- 2017-01-06 PT PT177364593T patent/PT3399984T/pt unknown
- 2017-01-06 SG SG11201805506YA patent/SG11201805506YA/en unknown
- 2017-01-06 EA EA201891583A patent/EA038565B1/ru unknown
- 2017-01-06 JP JP2018554643A patent/JP6920344B2/ja active Active
- 2017-01-06 ES ES17736459T patent/ES2963759T3/es active Active
- 2017-01-06 HU HUE17736459A patent/HUE063388T2/hu unknown
- 2017-01-06 TW TW106100542A patent/TWI744274B/zh active
- 2017-01-06 PL PL17736459.3T patent/PL3399984T3/pl unknown
- 2017-01-06 TW TW110136486A patent/TW202227095A/zh unknown
- 2017-01-06 CN CN202210014893.XA patent/CN114395005B/zh active Active
- 2017-01-06 LT LTEPPCT/US2017/012587T patent/LT3399984T/lt unknown
- 2017-01-06 CN CN202411958636.7A patent/CN119912510A/zh active Pending
- 2017-01-06 EP EP23194905.8A patent/EP4306525A3/en active Pending
- 2017-01-06 DK DK17736459.3T patent/DK3399984T3/da active
- 2017-01-06 MX MX2018008350A patent/MX2018008350A/es unknown
- 2017-01-06 KR KR1020187022597A patent/KR102772803B1/ko active Active
- 2017-01-06 UA UAA201808490A patent/UA124529C2/uk unknown
- 2017-01-06 MY MYPI2018001218A patent/MY204877A/en unknown
- 2017-01-06 HR HRP20231155TT patent/HRP20231155T1/hr unknown
-
2018
- 2018-06-25 PH PH12018501361A patent/PH12018501361A1/en unknown
- 2018-06-28 ZA ZA2018/04350A patent/ZA201804350B/en unknown
- 2018-07-05 CL CL2018001845A patent/CL2018001845A1/es unknown
- 2018-07-05 MX MX2022006322A patent/MX2022006322A/es unknown
- 2018-07-05 SA SA518391985A patent/SA518391985B1/ar unknown
-
2019
- 2019-02-12 US US16/273,843 patent/US10981944B2/en active Active
-
2020
- 2020-09-01 US US17/009,590 patent/US11001603B2/en active Active
-
2021
- 2021-03-19 US US17/206,896 patent/US11667662B2/en active Active
- 2021-07-26 JP JP2021121236A patent/JP7322104B2/ja active Active
-
2022
- 2022-08-24 ZA ZA2022/09472A patent/ZA202209472B/en unknown
-
2023
- 2023-03-02 AU AU2023201288A patent/AU2023201288B2/en active Active
- 2023-07-26 JP JP2023121750A patent/JP7698677B2/ja active Active
- 2023-11-21 US US18/516,459 patent/US12459967B2/en active Active
-
2025
- 2025-06-13 JP JP2025099433A patent/JP2025123371A/ja active Pending